Therapeutic effect of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy: a meta-analysis

Abstract

Objective: To comprehensively evaluate therapeutic effect of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy.

Methods: The CNKI, WanFang, VIP, Chinese Biomedical Database (CBM), PubMed, Embase and Cochrane Library databases were searched to collect the randomized controlled trials (RCTs) of YiQi HuoXue BuShen decoction combined with Western medicine on hypertensive nephropathy, which were published as of March 10, 2023. Then, these articles were screened to extract and evaluate the data. Revman 5.3 was applied for data analysis.

Results: Eight RCTs involving 732 patients were included after screening. Comparing with Western medicine, YiQi HuoXue BuShen decoction combined with Western medicine enhanced the clinical effect [OR = 3.48, 95% CI: 2.12~5.73, P < 0.00001]; reduced 24-hour urine protein content [OR = -0.60, 95% CI: -0.92~-0.28, P = 0.0003], serum creatinine (Scr) [OR = -39.11, 95% CI: -44.72~-33.51, P < 0.00001], blood urea nitrogen (BUN) [OR = -2.51, 95% CI: -4.06~-0.95, P = 0.002], cystatin C (Cys-C) [OR = -0.30, 95% CI: -0.36~-0.25, P < 0.00001], Urine β2-microglobulin [OR = -0.42, 95% CI: -0.87~-0.02, P = 0.06]; and enhanced creatinine clear rate (Ccr) [OR = 3.24, 95% CI: 1.85~4.64, P < 0.00001]. In addition, the combination treatment didn't increase the incidence of adverse reaction compared with western medicine [OR = 1.55, 95% CI: 0.61~3.95, P > 0.05].

Conclusions: The combination of Yiqi Huoxue Bushen decoction and western medicine can effectively improve the clinical symptoms and renal function of patients with hypertensive nephropathy and provide more theoretical basis for clinical application.

Keywords: Western medicine; Yiqi Huoxue Bushen decoction; effect; hypertensive nephropathy.

Figure 1

Literature screening process.

Figure 2

The scale for assessing the quality of clinical trials.

Figure 3

Summary chart of the risk bias assessment.

Figure 4

The comparison of total effective rate between two groups.

Figure 5

The comparison of 24-hour urinary protein quantification between two groups.

Figure 6

The comparison of serum creatinine (Scr) between two groups.

Figure 7

The comparison of blood urea nitrogen (BUN) between two groups.

Figure 8

The comparison of cystatin C (Cys-C) between two groups.

Figure 9

The comparison of Urine β2-microglobulin between two groups.

Figure 10

The comparison of creatinine clear rate (Ccr) between two groups.

Figure 11

The comparison of adverse reaction between two groups.

Figure 12

Assessment of publication bias. A. The total clinical effective rate; B. 24-hour urinary protein quantification; C. Serum creatinine (Scr); D. Blood urea nitrogen (BUN); E. Cystatin C (Cys-C); F. Urine β2-microglobulin; G. Creatinine clear rate (Ccr); H. Adverse reaction.